STOCK TITAN
  1. Home
  2. News
  3. EVGN

EVOGENE LTD. - EVGN STOCK NEWS

Welcome to our dedicated page for EVOGENE LTD. news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on EVOGENE LTD. stock.

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a leading computational biology company leveraging big data and artificial intelligence to revolutionize the development of life-science-based products. The company, headquartered in Rehovot, Israel, employs cutting-edge technologies to increase the probability of success while reducing development time and cost across multiple market segments including human health, agriculture, and industrial applications. Evogene has established three unique tech-engines - MicroBoost AI, ChemPass AI, and GeneRator AI - each focused on products based on microbes, small molecules, and genetic elements respectively.

The company operates through several subsidiaries that utilize these tech-engines:

  • Biomica Ltd.: Develops microbiome-based therapeutics for diseases such as antibiotic-resistant bacteria, cancer, and gastrointestinal disorders.
  • Lavie Bio Ltd.: Focuses on microbiome-based ag-biologicals to enhance crop yield and sustainability.
  • AgPlenus Ltd.: Innovates in sustainable crop protection products.
  • Canonic Ltd.: Develops medical cannabis products.
  • Casterra Ag Ltd.: Produces high-yield castor seeds for biofuels and other industrial uses.

Evogene's recent achievements include securing new seed production agreements for Casterra, advancing clinical trials for Biomica's immuno-oncology candidate BMC128, and extending validation trials for Lavie Bio's biofungicides in collaboration with Bayer AG. Evogene has been proactive in addressing its Nasdaq listing compliance and continues to prioritize innovation through strategic partnerships and collaborative ventures. For more information, please visit www.evogene.com.

News

Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
clinical trial
-
News

Evogene Announces Pricing of US$8,500,000 Registered Direct Offering

Rhea-AI Summary
EVGN: Evogene Ltd. Announces Registered Direct Offering of 8,500,000 Ordinary Shares at $1.00 per Share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.71%
Tags
offering
-
News

Lavie Bio Announces Licensing Agreement for Bio-Fungicides with Corteva Agriscience

Rhea-AI Summary
Corteva Inc. (NYSE: CTVA) to receive exclusive rights to further develop and commercialize Lavie Bio's lead product candidates targeting fruit rot and powdery mildew. The agreement aims to address destructive diseases affecting vineyards, fruits, and vegetables, resulting in billions of dollars in annual losses globally. This collaboration demonstrates commitment to providing farmers with environmentally friendly, sustainable tools.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
News

AgPlenus Appoints Dr. Adrian Percy to Its Board of Directors

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.57%
Tags
management
-
News

Casterra Announces Additional $2.2 Million of Purchase Orders to Supply Castor Seeds for New African Territories

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.41%
Tags
none
-
News

Casterra Signs a Framework Agreement with a World Leading Oil and Gas Company to Sell Its Castor Seeds for Sustainable Biofuel Production, with Initial Purchase Orders of $9.1 Million

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.81%
Tags
none
News

Lavie Bio Receives Canadian Regulatory Approval for Thrivus™, Expanding Global Reach

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Evogene Reports First Quarter 2023 Financial Results

Rhea-AI Summary
Evogene Ltd. announces financial results for Q1 2023, highlighting improvements in AI tech-engines and milestones achieved by subsidiaries. Subsidiary Biomica closes $20 million investment round. Lavie Bio sees high market demand for bio-inoculant product. AgPlenus aims to develop weed-control herbicide. Canonic launches new cannabis products. Casterra secures agreement with major global energy company. Ag Seeds division receives €1.2 million EU grant. Consolidated cash position at $28.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
earnings
-
News

Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
News

Evogene Schedules First Quarter 2023 Financial Results Release & Conference Call for May 18, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings

FAQ

What is the current stock price of EVOGENE LTD. (EVGN)?

The current stock price of EVOGENE LTD. (EVGN) is $1.68 as of November 18, 2024.

What is the market cap of EVOGENE LTD. (EVGN)?

The market cap of EVOGENE LTD. (EVGN) is approximately 9.3M.

What does Evogene Ltd. do?

Evogene Ltd. is a computational biology company that uses AI and big data to develop life-science-based products in human health, agriculture, and industrial applications.

Where is Evogene Ltd. headquartered?

Evogene Ltd. is headquartered in Rehovot, Israel.

What are Evogene's main technology platforms?

Evogene has three main tech-engines: MicroBoost AI for microbes, ChemPass AI for small molecules, and GeneRator AI for genetic elements.

Who are some of Evogene's subsidiaries?

Evogene's subsidiaries include Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., Canonic Ltd., and Casterra Ag Ltd.

What is the focus of Biomica Ltd.?

Biomica Ltd. focuses on developing microbiome-based therapeutics for diseases such as antibiotic-resistant bacteria, cancer, and gastrointestinal disorders.

What recent partnerships has Evogene engaged in?

Evogene recently extended validation trials for Lavie Bio's biofungicides with Bayer AG, and secured new seed production agreements for Casterra.

How is Evogene addressing its Nasdaq listing compliance?

Evogene is actively working to regain compliance with Nasdaq's listing requirements and considers various options, including reverse share splits, to maintain its listing.

What are some recent achievements of Evogene Ltd.?

Evogene has advanced clinical trials for Biomica's BMC128, secured new seed production agreements for Casterra, and extended biofungicide validation trials with Bayer AG.

Where can I find more information about Evogene Ltd.?

More information about Evogene Ltd. can be found on their official website at www.evogene.com.

What market segments does Evogene target?

Evogene targets human health, agriculture, and industrial applications through its computational biology platforms and subsidiaries.

Stock EVGN logo
EVOGENE LTD.

Nasdaq:EVGN

EVGN Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

EVGN Stock Data

9.28M
5.37M
1.66%
7.87%
0.5%
Biotechnology
Healthcare
Link
United States of America
Rehovot